Itzhak Zachi Attia, an assistant professor of medicine and co-director of artificial intelligence (AI) in cardiology at Mayo Clinic, has filed for protection of an Al-based tool to detect cardiac amyloidosis (CA) from the analysis of voltage-time data captured from electrocardiograms (ECGs) acquired from a plurality of leads.
Rapidai Inc. landed $75 million in a series C financing led by Vista Credit Partners. The funds will be used to fuel development of additional indications and expand market reach of its artificial intelligence (AI)-powered clinical decisionmaking and workflow support technology. With this latest round, the San Mateo, Calif.-based company has raised approximately $100 million, according to Crunchbase.
The transformation of cardiology continues with two U.S. FDA actions to promote the use of artificial intelligence (AI): a 510(k) clearance for Rapidai Inc.’s pulmonary embolism (PE) triage and notification product and breakthrough device designation for Anumana Inc.’s pulmonary hypertension (PH) early detection algorithm.